Table 1.
Baseline characteristics by cohort
| Baseline characteristics | Rollover cohort (n = 82) | Switch cohort (n = 37) |
|---|---|---|
| Patient demographics | ||
| Age, years | 53.7 (12.3) | 52.4 (11.5) |
| Female, n (%) | 37 (45) | 15 (41) |
| White, n (%) | 76 (93) | 36 (97) |
| Education, years | 14.4 (2.6) | 14.5 (2.5) |
| Patient clinical characteristics | ||
| Body weight at screening, kg | 74.3 (15.0) | 71.4 (16.5) |
| BMI at screening, kg/m2 | 25.8 (4.6) | 23.9 (4.7) |
| UHDRS TFC | 9.6 (2.2) | 8.3 (2.1) |
| UHDRS TMCa | 12.0 (4.1) | 12.5 (5.3) |
| UHDRS TMSa | 34.7 (16.1) | 37.8 (18.6) |
| BARS: summary score | 1.1 (1.7) | 0.8 (1.3) |
| BARS: global clinical assessment | 0.5 (0.8) | 0.4 (0.7) |
| ESS: total score | 4.4 (3.7) | 6.0 (4.1) |
| HADS: anxiety subscale | 2.7 (3.0) | 4.3 (3.4) |
| HADS: depression subscale | 2.0 (2.5) | 3.4 (2.5) |
| MoCA: total score | 23.9 (4.4) | 21.9 (3.9) |
| SDQ: swallowing disturbance | 3.5 (3.1) | 4.7 (3.1) |
| UPDRS speech | 0.9 (0.8) | 1.1 (0.7) |
| UHDRS Parkinsonism | 10.5 (5.9) | 12.1 (6.9) |
| Stroop color | 46.8 (15.9) | 40.7 (12.9) |
| Stroop word | 58.4 (20.8) | 50.4 (16.2) |
| Stroop interference | 28.9 (15.1) | 21.7 (8.2) |
| Symbol digit modalities | 24.4 (8.9) | 22.7 (17.4) |
| Verbal fluency | 25.1 (11.0) | 21.5 (10.8) |
All values are mean (SD) unless otherwise noted
BARS Barnes Akathisia Rating Scale, BMI body mass index, ESS Epworth Sleepiness Scale, HADS Hospital Anxiety and Depression Scale, MoCA Montreal Cognitive Assessment, SD standard deviation, SDQ Swallowing Disturbance Questionnaire, TFC total functional capacity, TMC total maximal chorea, TMS total motor score, UHDRS Unified Huntington’s Disease Rating Scale, UPDRS Unified Parkinson’s Disease Rating Scale
aFor the Switch cohort, baseline values were the most recent available values prior to the first administration of the study drug; the baseline values for TMC and TMS were the means of the values from the screening and baseline visits. For the Rollover cohort, baseline values were the most recent available values obtained at least 4 days after the last administration of the First-HD study drug; baseline values for TFC were obtained from the original baseline visit, prior to the first administration of the First-HD study drug